GlassScriptPhysician profile
Gregory Kozielec
NPI 1053379081
$4,498.14
in general payments reported to CMS, 2019-2025
15 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,667 · 2020: $202 · 2021: $43.10 · 2022: $148 · 2023: $53.39 · 2024: $200 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.38 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $3,513.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $214.77 | 2020-2022 | |
| Genentech USA, INC. | $174.09 | 2022-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $110.46 | 2022-2025 | Eylea Hd |
| Abbvie INC. | $108.04 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $83.71 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.20 | 2019-2021 | |
| Eyepoint US, INC. | $43.50 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $37.84 | 2022 | |
| Alimera Sciences, INC. | $34.71 | 2019-2024 | Yutiq, Iluvien |
| Harrow Eye, LLC | $27.27 | 2024 | Iheezo |
| Ani Pharmaceuticals, INC. | $24.63 | 2025 | Yutiq |
| Amgen INC. | $19.85 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $19.49 | 2023 | Tepezza |
| Biogen, INC. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kozielec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.